ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company's stock.

A number of other brokerages have also issued reports on PRQR. JMP Securities reissued a "market outperform" rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target for the company in a research note on Monday, March 10th. Oppenheimer assumed coverage on ProQR Therapeutics in a research note on Friday, January 10th. They set an "outperform" rating and a $15.00 price target for the company. StockNews.com lowered ProQR Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, November 28th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $9.50.

Remove Ads

ProQR Therapeutics Trading Down 3.5 %

Shares of NASDAQ:PRQR traded down $0.06 during mid-day trading on Friday, reaching $1.64. The stock had a trading volume of 731,927 shares, compared to its average volume of 535,512. The company has a market cap of $133.96 million, a P/E ratio of -5.13 and a beta of 0.24. ProQR Therapeutics has a 1 year low of $1.61 and a 1 year high of $4.62. The business's 50 day moving average price is $2.23 and its 200 day moving average price is $2.62.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. lifted its holdings in shares of ProQR Therapeutics by 164.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock valued at $25,446,000 after buying an additional 5,976,813 shares during the period. Woodline Partners LP acquired a new position in ProQR Therapeutics in the 4th quarter worth about $9,426,000. Millennium Management LLC raised its holdings in ProQR Therapeutics by 1,864.4% in the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock worth $7,492,000 after purchasing an additional 2,683,351 shares during the period. Affinity Asset Advisors LLC acquired a new position in ProQR Therapeutics in the 4th quarter worth about $7,486,000. Finally, DAFNA Capital Management LLC raised its holdings in ProQR Therapeutics by 73.1% in the 4th quarter. DAFNA Capital Management LLC now owns 1,567,561 shares of the biopharmaceutical company's stock worth $4,154,000 after purchasing an additional 661,979 shares during the period. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).